Abstract
Cardiac involvement in systemic light chain amyloidosis (AL) is generally associated with a worse outcome, especially if other organs are also involved. We sought to determine whether concurrent cardiac and renal involvement were associated with a worse outcome than either organ alone. We identified 129 patients with AL, who received high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HCT) at our institution between 1997 and 2014. Ninety-nine patients had either renal (group 1: n = 62, 62%), cardiac (group 2: n = 20, 20%), or both cardiac and renal (group 3: n = 17, 17%) involvement. The overall hematological response rate (CR+VGPR+PR) post-auto-HCT in groups 1, 2, and 3 was 69%, 74% and 82%, respectively (P = 0.62). Overall, organ response in groups 1, 2, and 3 was 39%, 42%, and 70%, respectively. The median PFS from auto-HCT in groups 1, 2, and 3 was not reached (NR), 13.3 and 21 months, respectively (P = 0.02). The median OS in groups 1, 2, and 3 was 120, 46, and 60 months, respectively (P = 0.1). In conclusion, median PFS and OS in patients with concurrent cardiac and renal AL were comparable to patients with cardiac AL only, but worse than patients with renal AL.
References
Aug 15, 1997·The American Journal of Cardiology·A R PatelR Davidoff
Sep 26, 1997·The New England Journal of Medicine·R H FalkM Skinner
Nov 13, 2001·Bone Marrow Transplantation·V SanchorawalaM Skinner
Dec 3, 2002·The American Journal of Medicine·Morie A GertzMark R Litzow
Nov 7, 2003·The New England Journal of Medicine·Cem I Sungur
Jan 22, 2004·Annals of Internal Medicine·Martha SkinnerDaniel G Wright
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela DispenzieriAllan S Jaffe
Jul 27, 2005·Bone Marrow Transplantation·V SanchorawalaD G Wright
Jul 27, 2005·American Journal of Hematology·Morie A GertzGiles Grateau
Aug 23, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Nelson LeungMorie A Gertz
Nov 16, 2005·Transplantation·Stefan O SchonlandHartmut Goldschmidt
Feb 21, 2006·Wiener klinische Wochenschrift·Nina WorelHildegard T Greinix
Sep 9, 2006·Blood·Vaishali SanchorawalaDavid C Seldin
Sep 23, 2006·Blood·Ashutosh D WechalekarJulian D Gillmore
Feb 3, 2007·Current Opinion in Oncology·Morie A GertzShaji Kumar
Sep 15, 2007·The New England Journal of Medicine·Arnaud JaccardUNKNOWN Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup
Aug 28, 2010·Blood·Shaji KumarMorie A Gertz
Dec 25, 2010·American Journal of Hematology·S Vincent Rajkumar
Feb 18, 2011·American Journal of Hematology·Shaji K KumarMorie A Gertz
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giampaolo MerliniMorie A Gertz
May 6, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Sandra M S HerrmannNelson Leung
Aug 24, 2011·Haematologica·Vaishali SanchorawalaDavid C Seldin
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaji KumarMorie A Gertz
Jan 11, 2013·Kidney International·Samih H NasrNelson Leung
Mar 13, 2013·Blood·Ashutosh D WechalekarGiovanni Palladini
Jun 3, 2014·Bone Marrow Transplantation·S ParmarM H Qazilbash
Aug 15, 2014·Blood·Giovanni PalladiniStefan Schönland